Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Music Perception in SeLECTs

NCT06545708 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-11-13
Last updated
2024-12-09

Condition(s) studied

Rolandic Epilepsy

Investigational drug(s) / intervention(s)

Patients

Patients: This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.

Study summary

Self-limited epilepsy with centrotemporal spikes (SeLECTS) is the most frequent epilepsy syndrome in children between the ages of 4 and 13 years. SeLECTS is associated in 15 to 30% of patients with specific cognitive deficits, including in particular disorders in language, visuo-spatial memory, declarative memory, and attention. SeLECTS has the potential to evolve into Landau-Kleffner syndrome, the most extreme form of SeLECTS including symptoms of auditory agnosia and aphasia, with potential risks of persistent neuropsychological impairments. In a recent study in adults who had suffered Landau-Kleffner syndrome during childhood, the investigators have shown that these patients, in addition to their known deficit in verbal short-term memory, also exhibit persistent musical difficulties during adulthood, with in particular deficit in melody and rhythm short-term memory.

In the present project, the investigators intend to enlarge the understanding of cognitive deficits generated by SeLECTS in children by investigating the integrity of music perception, both for melody and rhythm. To date, data about music perception in children with epilepsy are scarce and we do not know how distinct components of melody and rhythm perception and memory may be altered.

Eligibility

Sex
ALL
Min age
5 Years
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: * Subject aged between 5 and 14 years old * Non-opposition of parents or guardians for the child's participation in the study * No major cognitive impairment and ability to understand and apply instructions * Subject affiliated to a social security scheme * Subject motivated to participate in the project * Proficiency with the French language For the group of control participants: • Without neurological or psychiatric history For the group of participants with seizure disorder: * No neurological (except EPCT) or psychiatric history * Diagnosis of self-limited epilepsy with centro-temporal spikes (PTSE) by a qualified healthcare professional. Exclusion Criteria: * Major cognitive impairment or inability to understand and apply instructions * Individuals refusing to participate in the study * Pregnant or breastfeeding minors

Primary outcome measure(s)

  • Performance obtained in melodic tasks — 2 Years
    Comparison between controls and patients using Bayesian ANOVAs to the percentages of correct responses obtained with melodic tasks
  • Performance obtained in melodic tasks — 2 Years
    Comparison between controls and patients using Bayesian ANOVAs to response times obtained with melodic tasks;
  • Performance obtained in rhythmic tasks — 2 Years
    Comparison between controls and patients using Bayesian ANOVAs to the percentages of correct responses obtained with rhythmic tasks
  • Performance obtained in rhythmic tasks — 2 Years
    Comparison between controls and patients using Bayesian ANOVAs to response times obtained with rhythmic tasks.

Trial sites (2)

FacilityCityRegionStatus
Centre Hospitalier Le Vinatier (Bât. 452), Bron Bron Not Yet Recruiting
Hospices Civils de Lyon Bron Bron Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06545708 on ClinicalTrials.gov ↗ ← All trials in France